Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Non-current Assets
All assets not expected to be converted to cash within one year.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 2535.5% from a year ago
Total non-current assets stood at $239.88K at the end of Q1 FY2026, up 2535.5% from a year earlier and down 5.9% from the prior quarter. Over 3 fiscal years it compounded at +60.9% a year.
Context
- Total non-current assets amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +2535.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 254.92K USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 254.92K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 12.65K | -79.3% |
| FY2022 | 2022-12-31 | 61.23K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Assets vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +2535.5% is the highest of 11, against a peer median of +20.6%.
- Total non-current assets amounts to 0.2% of total assets for MNPR, versus a peer median of 11.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $644.02M USD | +510.1% | +2.8% | 54.7% | |
| Jun 2026 | $201.75M USD | -44.9% | +17.3% | 27.8% | |
| Mar 2026 | $35.35M USD | -16.8% | -18.2% | 16.2% | |
| Mar 2026 | $33.26M USD | +19.6% | -5.6% | 5.1% | |
| Mar 2026 | $32.76M USD | +78.4% | -38.4% | 18.4% | |
| Sep 2026 | $27.73M USD | +42.6% | +152.2% | 5.5% | |
| Dec 2025 | €16M EUR | -36.8% | -38.3% | 25.5% | |
| Mar 2026 | $14.73M USD | +1.2% | -33.0% | 5.1% | |
| Mar 2026 | $9.48M USD | +29.8% | +26.3% | 4.6% | |
| Jun 2026 | $2.42M USD | +21.6% | -9.7% | 6.0% | |
| Mar 2026 | $239.88K USD | +2535.5% | +60.9% | 0.2% | |
| Peer median (excluding MNPR) | — | +20.6% | -7.6% | 11.1% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.